These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 29877131

  • 21. Botulinum toxin type A in refractory chronic migraine: an open-label trial.
    Menezes C, Rodrigues B, Magalhães E, Melo A.
    Arq Neuropsiquiatr; 2007 Sep; 65(3A):596-8. PubMed ID: 17876397
    [Abstract] [Full Text] [Related]

  • 22. Decreased Pulmonary Function During Botulinum Toxin A Therapy for Chronic Migraines in a 17-Year-Old Female.
    Oliver JD, Boesch RP, Mack KJ.
    Headache; 2018 Sep; 58(8):1259-1261. PubMed ID: 30033516
    [No Abstract] [Full Text] [Related]

  • 23. Onabotulinumtoxin [corrected] A (Botox).
    Tepper D.
    Headache; 2014 Apr; 54(4):787-8. PubMed ID: 24697235
    [No Abstract] [Full Text] [Related]

  • 24. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 25. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
    Tassorelli C, Aguggia M, De Tommaso M, Geppetti P, Grazzi L, Pini LA, Sarchielli P, Tedeschi G, Martelletti P, Cortelli P.
    J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
    [Abstract] [Full Text] [Related]

  • 26. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
    de Tommaso M, Brighina F, Delussi M.
    Eur Neurol; 2019 Dec; 81(1-2):37-46. PubMed ID: 31013496
    [Abstract] [Full Text] [Related]

  • 27. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
    Lyseng-Williamson KA, Frampton JE.
    CNS Drugs; 2012 Aug 01; 26(8):717-23. PubMed ID: 22784019
    [Abstract] [Full Text] [Related]

  • 28. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 29. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J.
    Headache; 2014 Jun 15; 54(6):987-95. PubMed ID: 24673487
    [Abstract] [Full Text] [Related]

  • 30. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.
    Maasumi K, Thompson NR, Kriegler JS, Tepper SJ.
    Headache; 2015 Oct 15; 55(9):1218-24. PubMed ID: 26381856
    [Abstract] [Full Text] [Related]

  • 31. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, Sansebastiano GE, Torelli P.
    Neurol Sci; 2016 Jul 15; 37(7):1127-31. PubMed ID: 27048312
    [Abstract] [Full Text] [Related]

  • 32. Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.
    Ceccardi G, Schiano di Cola F, Caratozzolo S, Di Pasquale M, Bolchini M, Padovani A, Rao R.
    Toxins (Basel); 2023 Nov 30; 15(12):. PubMed ID: 38133181
    [Abstract] [Full Text] [Related]

  • 33. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
    Quintas S, García-Azorín D, Heredia P, Talavera B, Gago-Veiga AB, Guerrero ÁL.
    Pain Med; 2019 Sep 01; 20(9):1815-1821. PubMed ID: 30657951
    [Abstract] [Full Text] [Related]

  • 34. Botox for chronic migraine.
    Drug Ther Bull; 2011 Feb 01; 49(2):22-4; quiz iii-iv. PubMed ID: 21304165
    [Abstract] [Full Text] [Related]

  • 35. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P.
    J Headache Pain; 2020 Jul 11; 21(1):88. PubMed ID: 32652924
    [Abstract] [Full Text] [Related]

  • 36. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 11; 30(7):804-14. PubMed ID: 20647171
    [Abstract] [Full Text] [Related]

  • 37. Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.
    Algahtani H, Shirah B, Sukkar G, Bukhari H, Meftah I, Alhazmi A, Alshareef A, Algethami A, Alshanqiti A, Andeejani M.
    Acta Neurol Belg; 2021 Dec 11; 121(6):1783-1787. PubMed ID: 33058053
    [Abstract] [Full Text] [Related]

  • 38. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study.
    Lin KH, Chen SP, Fuh JL, Wang YF, Wang SJ.
    J Chin Med Assoc; 2014 Jan 11; 77(1):10-5. PubMed ID: 24269600
    [Abstract] [Full Text] [Related]

  • 39. [Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].
    Palma JA, Irimia P, Fernandez-Torron R, Ortega-Cubero S, Riverol M, Luquin MR, Martinez-Vila E.
    Rev Neurol; 2012 Jun 16; 54(12):705-11. PubMed ID: 22673946
    [Abstract] [Full Text] [Related]

  • 40. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group.
    Headache; 2005 Apr 16; 45(4):293-307. PubMed ID: 15836565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.